Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
Debra J Tompson,1 Christopher S Crean,2 Mauro Buraglio,1 Thangam Arumugham3 1Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage, Hertfordshire, UK; 2Clinical Pharmacology and Pharmacokinetics, Valeant Pharmaceuticals North America, Durham, NC, USA; 3Clinical Statistics, Glax...
Guardado en:
Autores principales: | Tompson DJ, Crean CS, Buraglio M, Arumugham T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a39ebd84ab9c42aa8ea85e3337382a26 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
por: Weisenberg JLZ, et al.
Publicado: (2011) -
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost C, et al.
Publicado: (2017) -
Efficiency of individual dosage of digoxin with calculated concentration
por: Zhao L, et al.
Publicado: (2014) -
Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
por: Ghasemiyeh P, et al.
Publicado: (2020) -
Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Hongrui Liu, et al.
Publicado: (2021)